Ferrari v. Vitamin Shoppe Industries LLC ( 2023 )


Menu:
  •             United States Court of Appeals
    For the First Circuit
    No. 22-1332
    RICHARD FERRARI, individually and on behalf of all others
    similarly situated; WILLIAM BOHR, individually and on behalf of
    all others similarly situated,
    Plaintiffs, Appellants,
    v.
    VITAMIN SHOPPE INDUSTRIES LLC f/k/a Vitamin Shoppe Inc.,
    Defendant, Appellee.
    APPEAL FROM THE UNITED STATES DISTRICT COURT
    FOR THE DISTRICT OF MASSACHUSETTS
    [Hon. George A. O'Toole, Jr., U.S. District Judge]
    Before
    Montecalvo and Thompson, Circuit Judges,
    and Carreño-Coll, District Judge.
    Mark R. Sigmon, with whom Nick Suciu, III, Milberg Coleman
    Bryson Phillips Grossman PLLC, Charles J. LaDuca, Brendan S.
    Thompson, Cuneo Gilbert & LaDuca, LLP, Joseph J. Siprut, Erica C.
    Mirabella, Charles E. Schaffer, and Levin Sedran & Berman LLP were
    on brief, for appellants.
    Michael R. McDonald, with whom Caroline E. Oks and Gibbons,
    P.C. were on brief, for appellee.
       Of the District of Puerto Rico, sitting by designation.
    June 9, 2023
    CARREÑO-COLL,       District    Judge.     Richard    Ferrari     and
    William Bohr purchased three dietary supplements with glutamine in
    the hope that the glutamine would -- as the labels said -- help
    their muscles grow and recover after intense exercise.                   When they
    did not see any results, they sued the products' manufacturer,
    Vitamin Shoppe, for several state torts.                  The district court
    granted   summary     judgment      to    Vitamin   Shoppe,     ruling   that   the
    plaintiffs' state law claims are preempted because the labels
    comply with federal law.           We affirm.
    I.
    The Food, Drug, and Cosmetic Act ("FDCA") is designed to
    protect       consumers     from        harmful     products.        Perham      v.
    GlaxoSmithKline       LLC   (In    re    Zofran   (Ondansetron)    Prods.     Liab.
    Litig.), 
    57 F.4th 327
    , 330 (1st Cir. 2023).               Congress amended the
    FDCA through the Dietary Supplement Health and Education Act of
    1994 ("DSHEA") to establish a uniform framework to regulate dietary
    supplements.      
    Pub. L. No. 103-417, 108
     Stat. 4325, 4325–26 (1994).
    Under   the    FDCA   and    DSHEA,      manufacturers    may    make    so-called
    "structure/function claims" about dietary supplements.                     Kaufman
    v. CVS Caremark Corp., 
    836 F.3d 88
    , 92 (1st Cir. 2016).                           A
    structure/function claim "describes the role of a nutrient or
    dietary ingredient intended to affect the structure or function in
    humans" or "characterizes the documented mechanism by which a
    nutrient or dietary ingredient acts to maintain such structure or
    - 3 -
    function."        
    21 U.S.C. § 343
    (r)(6)(A).           That a nutrient, for
    example, "helps promote digestion" or "supports the immune system"
    is a structure/function claim.        Regulations on Statements Made for
    Dietary Supplements Concerning the Effect of the Product on the
    Structure or Function of the Body, 
    65 Fed. Reg. 1000
    , 1006, 1028–
    29 (Jan. 6, 2000) (codified at 21 C.F.R. pt. 101).               To make such
    a claim, the manufacturer must have "substantiation that [the
    claim] is truthful and not misleading."             § 343(r)(6)(B).      And the
    dietary supplement's label must bear a disclaimer stating that the
    claim has not been evaluated by the Food and Drug Administration
    ("FDA") and that the "product is not intended to diagnose, treat,
    cure, or prevent any disease."             § 343(r)(6)(C).       Finally, the
    claim itself may not purport "to diagnose, mitigate, treat, cure,
    or prevent" disease.       § 343(r)(6).
    If   the   manufacturer's     label    satisfies   § 343(r)(6)'s
    requirements, consumers          may not   attack the     structure/function
    claim under state law.       See Kaufman, 
    836 F.3d at
    91–92.             To keep
    labeling requirements uniform, the FDCA expressly preempts "any
    requirement" under state law "respecting any claim of the type
    described in section 343(r)(1) . . . made in the label or labeling
    of food that is not identical to the requirement of section
    343(r)."      
    21 U.S.C. § 343-1
    (a)(5).             Structure/function claims
    under   § 343(r)(6)       fall    within     § 343(r)(1)'s      ambit.       See
    § 343(r)(6) (stating that, "[f]or purposes of paragraph (r)(1)(B),
    - 4 -
    a statement for a dietary supplement may be made if" the statement
    complies with certain requirements).            So they are "claim[s] of the
    type described in section 343(r)(1)."              And they are claims made
    in the labeling of food because dietary supplements are "deemed"
    food under the FDCA, except in limited circumstances that do not
    apply here.     See 
    21 U.S.C. § 321
    (ff).           Thus, the FDCA expressly
    preempts any state law that establishes labeling requirements for
    structure/function     claims      that     are    not    identical   to   the
    requirements in § 343(r)(6).        See Dachauer v. NBTY, Inc., 
    913 F.3d 844
    , 847–48 (9th Cir. 2019).       The "net effect" of this is that the
    manufacturer "prevail[s] if its label satisfies the requirements
    of [§ 343(r)(6)]."     Kaufman, 
    836 F.3d at 92
    .
    With our statutory scaffolding in place, we turn to what
    happened     below.        The   plaintiffs       purchased   three   dietary
    supplements:     Glutamine, Creatine & Glutamine with Beta-Alanine,
    and BCAA & Glutamine.1      Glutamine is a main ingredient in all three
    of them.      The Glutamine supplement states that glutamine "is
    involved in regulating protein synthesis and has been shown to
    possess [a]nti-[c]atabolic properties2 to help preserve muscle"
    and   that    "[i]ntense    exercise      can   deplete   glutamine   stores,
    1Ferrari purchased Creatine & Glutamine with Beta-Alanine,
    and Bohr purchased Glutamine and BCAA & Glutamine. We group the
    products together for analytical ease.
    2An anti-catabolic substance reduces the breakdown of muscle
    proteins.
    - 5 -
    however, supplemental glutamine is thought to replenish these
    stores allowing for enhanced recovery."    The Creatine & Glutamine
    with Beta-Alanine supplement says that "[g]lutamine helps support
    muscle growth and recovery as well as immune health."3       And the
    BCAA & Glutamine supplement states that glutamine has "anti-
    catabolic    properties."    The   plaintiffs   claimed   that   these
    statements are false and misleading under state law.
    Vitamin Shoppe moved for summary judgment on the ground
    that the FDCA preempts the plaintiffs' state law claims because
    its products' labels comply with § 343(r)(6).        The plaintiffs
    responded that the labels' statements about glutamine are claims
    about supplemental glutamine -- not naturally occurring glutamine
    (glutamine that the body produces) -- and so to comply with
    § 343(r)(6), Vitamin Shoppe needed to substantiate those claims
    3 There is some sparring in the briefing about whether two
    additional claims on this product -- "[c]reatine helps to improve
    strength and performance during high intensity exercise and
    training" and "[b]eta-alanine helps support muscle strength,
    endurance and overall athletic performance" -- are at issue.
    Vitamin Shoppe contends that this appeal is limited to claims about
    glutamine.     The plaintiffs insist that they have "always
    challenged" these two additional claims. But in their complaint,
    the plaintiffs bolded only the product's statement about
    glutamine, and their opposition to Vitamin Shoppe's motion for
    summary judgment did not contest the other claims.       Thus, any
    appellate argument based on those claims is waived. See Davis v.
    Lucent Techs., Inc., 
    251 F.3d 227
    , 232 (1st Cir. 2001) ("[W]here
    a plaintiff fails to present arguments to the district court in
    opposition to a defendant's motion for summary judgment, we have
    refused to consider those arguments for the first time on
    appeal.").
    - 6 -
    with       evidence   about    supplemental     glutamine.     Because      Vitamin
    Shoppe, they asserted, substantiated its claims about supplemental
    glutamine with evidence about naturally occurring glutamine, the
    claims are not substantiated within the meaning of § 343(r)(6) and
    thus the FDCA does not preempt their state law claims.
    The district court granted summary judgment to Vitamin
    Shoppe, ruling that the FDCA preempts the plaintiffs' state law
    claims.       In doing so, it held that the contested statements about
    glutamine       are    structure/function       claims,    that     there   is   no
    "meaningful       distinction"     in   the     record    between    supplemental
    glutamine and naturally occurring glutamine, and that the parties'
    experts largely agreed that glutamine does what Vitamin Shoppe's
    labels claim.         This appeal followed.
    II.
    We review de novo the district court's order granting
    summary judgment.         Perham, 57 F.4th at 335.           Through that lens,
    we view the facts in the record in the light most favorable to the
    plaintiffs, as the nonmovants, and draw all reasonable inferences
    in their favor.4         Id.    The district court's preemption ruling is
    The parties disagree about whether we should defer to the
    4
    district court's resolution of factual disputes subsumed within
    the preemption question:    Vitamin Shoppe argues that we should
    review the court's findings for clear error, whereas the plaintiffs
    imply that we should disregard its findings and view the record in
    the light most favorable to them as the nonmovants. Because we
    would affirm the district court under either standard, we view the
    facts in the more appellant-friendly way -- in the light most
    - 7 -
    reviewed de novo, too, because it "presents a pure question of
    law."    Medicaid & Medicare Advantage Prods. Ass'n of P.R., Inc.
    v. Hernández, 
    58 F.4th 5
    , 11 (1st Cir. 2023).
    III.
    The plaintiffs argue that the district court erred by
    holding that the FDCA preempts their state law claims because the
    statements about glutamine on Vitamin Shoppe's labels are not
    structure/function claims and, even if they were, Vitamin Shoppe
    lacks substantiation that the statements are truthful and not
    misleading.5    We take each argument in turn.
    A.
    We begin with whether the statements about glutamine on
    Vitamin Shoppe's labels are structure/function claims.        Recall
    that a structure/function claim describes a nutrient's effect on
    the human body's structure or function or explains how the nutrient
    maintains that structure or function.      § 343(r)(6)(A).   Vitamin
    Shoppe's statements about glutamine fit the bill.
    First, the statement "[i]ntense exercise can deplete
    glutamine stores, however, supplemental glutamine is thought to
    replenish these stores allowing for enhanced recovery"6 explains
    favorable to the plaintiffs.
    5 The plaintiffs do not challenge the district court's
    conclusion that Vitamin Shoppe satisfied § 343(r)(6)'s other
    requirements. So we need not dwell on them.
    6   The plaintiffs concede that the other claim on the Glutamine
    - 8 -
    how supplemental glutamine helps maintain glutamine stores, which
    help our muscles recover after intense exercise.       So it fits
    comfortably within the definition of a structure/function claim.
    Indeed, the FDA has approved of a substantially similar claim:
    "[The] FDA believes that a claim that a product is useful because
    it counterbalances the effects of a drug in depleting a nutrient
    . . . would be acceptable as a structure/function [claim]."     65
    Fed. Reg. at 1029.    The plaintiffs assert that this statement
    "go[es] too far" because by referring to a "specific situation and
    usage," Vitamin Shoppe is claiming that the product itself has
    this beneficial effect.   But their reading finds no support in the
    text of the statement.    The statement claims that supplemental
    glutamine is thought to replenish glutamine stores after intense
    exercise -- not that taking the product will replenish glutamine
    stores after intense exercise.   Although this distinction may be
    lost on consumers, it is a "form of finesse" that § 343(r)(6)(A)
    allows.   Cf. Kaufman, 
    836 F.3d at 96
     (stating that drawing a
    "distinction between the ingredient's function" and its effect on
    health "likely tricks many consumers," but the FDCA allows this
    "form of finesse").
    supplement, which says that glutamine "is involved in regulating
    protein synthesis and has been shown to possess [a]nti-[c]atabolic
    properties to help preserve muscle," is a structure/function
    claim.
    - 9 -
    Next,   the   statements      that   glutamine    "helps   support
    muscle growth and recovery as well as immune health" and has "anti-
    catabolic properties" are structure/function claims, too.                    For
    each describes how glutamine affects a structure or function in
    the human body.      And these claims are substantially similar to
    others that the FDA has blessed, such as "supports the immune
    system" and "boosts stamina, helps increase muscle size, and helps
    enhance muscle tone."        See 65 Fed. Reg. at 1028–30.
    The plaintiffs nonetheless contend that these statements
    are   not   structure/function      claims   because   they    refer    to   the
    products -- not just to the nutrient glutamine.              For example, the
    Glutamine supplement talks about supplemental glutamine (i.e., the
    form of the nutrient in the product), one of the statements about
    glutamine    is   prefaced    by   the   phrase    "[a]lso    added    [to   the
    product]," and one of the labels says that the product "combines"
    three nutrients before listing each with a description of the
    nutrient's physiological role.            The plaintiffs' contention is
    rooted in some language from Greenberg v. Target Corp., 
    985 F.3d 650
     (9th Cir. 2021).         Greenberg, in emphasizing the differences
    between structure/function claims and another type of claim called
    disease claims, said that a structure/function claim does not
    "refer to the product itself."           Id. at 654.   A disease claim, in
    contrast, "refers to a statement that the product itself can cure
    or treat a disease."      Id.      But Greenberg did not say that merely
    - 10 -
    noting that the nutrient is in the product negates an otherwise
    acceptable structure/function claim.               See id.       Nor do we see any
    reason why it would.              After all, a structure/function claim is
    about a nutrient or dietary ingredient in the product.                               See
    § 343(r)(6) (listing           claims that       can be made "for a dietary
    supplement"); 65 Fed. Reg. at 1002 (stating that the FDA's "final
    rule establishes criteria for determining whether a statement made
    about a dietary supplement is acceptable as a structure/function
    claim under section 403(r)(6)").
    The plaintiffs' last line of attack is that a reasonable
    jury could construe the contested statements about glutamine as
    claims       about   the    products'   benefits       instead   of   claims    about
    glutamine's effect on the human body.                  Assuming that the jury has
    a     role     to    play    in    deciding   whether       a    statement      is    a
    structure/function claim, no reasonable jury would construe the
    contested language as discussing the products' benefits instead of
    glutamine's         physiological    role.       The    statements    plainly    make
    claims about what glutamine does -- not about what the products
    do.    That a consumer might hope or infer that the product will do
    what the nutrient does is a far cry from a reasonable jury finding
    that the words "nutrient X does Y" is best construed as meaning
    "product Z does Y because it contains nutrient X."7
    In the end, the plaintiffs all but abandon their argument
    7
    that the contested statements are not structure/function claims.
    - 11 -
    In sum, because the contested statements about glutamine
    on Vitamin Shoppe's labels describe glutamine's effect on the human
    body's structure or function or explain how glutamine maintains
    that structure or function, they are structure/function claims
    under § 343(r)(6)(A).
    B.
    The plaintiffs argue next that the FDCA does not preempt
    their     state   law    claims     because    Vitamin     Shoppe    failed    to
    substantiate      its   products'    statements    about    glutamine.        They
    assert that the evidence substantiating each structure/function
    claim must be about the supplemental form of the nutrient.               Because
    the district court, they say, looked at evidence about naturally
    occurring glutamine rather than supplemental glutamine, it did not
    realize    that   Vitamin   Shoppe's       statements    about   glutamine    are
    bereft of evidentiary support.
    To make a structure/function claim, the manufacturer
    must "ha[ve] substantiation that [the claim] is truthful and not
    misleading."      § 343(r)(6)(B).       The term "substantiation" is not
    defined.    Kaufman, 
    836 F.3d at 93
    .          But the FDA's guidance defines
    it as "competent and reliable scientific evidence."                 
    Id.
     (quoting
    They say in their reply brief that "the best and most consistent
    position may be . . . that the claims here are proper-in-form
    structure/function claims." And at oral argument, they conceded
    that the statements are structure/function claims at "some level."
    - 12 -
    Food & Drug Admin., Guidance for Industry: Substantiation for
    Dietary Supplement Claims Made Under Section 403(r)(6) of the
    Federal Food, Drug, and Cosmetic Act          Part I.B. (Dec.       2008),
    http://www.fda.gov/food/guidanceregulation/guidancedocumentsregu
    latoryinformation/dietarysupplements/ucm073200.htm          [hereinafter
    Guidance for Industry]).       Because we have used that definition
    before, see 
    id.,
     and both parties use it, we will also do so here.
    Thus, to comply with § 343(r)(6)(B), Vitamin Shoppe must have
    competent     and   reliable     scientific     evidence     that     its
    structure/function claims about glutamine are truthful and not
    misleading.    Before we decide whether it has that evidence, we
    resolve first a dispute about which form of glutamine the evidence
    must be about.
    The plaintiffs argue that the evidence substantiating
    Vitamin Shoppe's structure/function claims about glutamine must be
    about the supplemental form, not the naturally occurring form.
    They are right for the simple reason that Vitamin Shoppe's claims
    are about supplemental glutamine and so its substantiation must
    be, too.    One of the labels openly talks about what "supplemental
    glutamine" does.    On another label, the statement about glutamine
    is prefaced by the phrase "[a]lso added," which means that the
    claim is about supplemental glutamine -- the glutamine added to
    the product -- not naturally occurring glutamine.          The statement
    about glutamine on the third label appears in a list of three
    - 13 -
    nutrients "combine[d]" in the product.                So this statement also
    refers to the form of glutamine in the product.                       Because the
    structure/function claims here are about supplemental glutamine,
    "substantiation that [the claims are] truthful and not misleading"
    must be about supplemental glutamine, too.8               See § 343(r)(6)(B).
    But    in    the   end,   the   distinction     between     naturally
    occurring glutamine and supplemental glutamine is, as the district
    court    said,     meaningless.       At    oral    argument,    we    asked   the
    plaintiffs    if    supplemental      glutamine     and   naturally     occurring
    glutamine play the same role in the human body.                  The plaintiffs
    conceded that, on this record, they do.              Our review of the record
    reveals only one difference between them:                 The parties' experts
    agreed    that     our   bodies   may   struggle      absorbing       supplemental
    glutamine    and    that   therefore    much   of    it   may   be    lost   during
    digestion.       But some of it survives.            Indeed, the plaintiffs'
    8  The plaintiffs' "first reason" why evidence about
    supplemental glutamine is required (i.e., that the claims are about
    supplemental glutamine) suffices here.    They nonetheless ask us
    to go further: They ask us to hold that every structure/function
    claim must be substantiated by evidence about the supplemental
    form of the nutrient. We see no reason to set down a hardline
    rule in a case that does not call for one, especially given the
    wide array of substances in dietary supplements and the wide array
    of forms they take. See 
    21 U.S.C. § 321
    (ff) (defining "dietary
    supplement" as a product that, among other things, contains "a
    vitamin," "a mineral," "an herb or other botanical," "an amino
    acid," "a dietary substance for use by man to supplement the diet
    by increasing the total dietary intake," or "a concentrate,
    metabolite, constituent, extract, or combination of any ingredient
    described").
    - 14 -
    expert acknowledged that some people -- such as those who exercise
    intensely      or   have   suffered     physical   trauma,   severe     illness,
    surgery, or burns -– benefit from taking supplemental glutamine.
    So where does that leave the disagreement between the parties?
    The plaintiffs contended at oral argument that Vitamin Shoppe loses
    on substantiation "if you take a pill and it does not actually
    affect the body's structure or function as the label claims."
    Section   343(r)(6)(B),       they    said,    requires   "efficacy   that    the
    product supports the body's structure or function as claimed."
    Vitamin Shoppe argues that the plaintiffs are seeking to impose a
    substantiation requirement above and beyond what the plain text of
    § 343(r)(6)(B) requires.
    With the facts and arguments ironed out, this case now
    looks a lot like Greenberg.             The issue there was whether Target
    had substantiation that its claim that biotin "helps support
    healthy hair and skin" was truthful and not misleading when the
    evidence showed that most people get the biotin they need through
    their diet and thus taking biotin is useless for all but a select
    few who have a biotin deficiency.             Greenberg, 985 F.3d at 652–53.
    The appellant argued that Target's "structure/function claim must
    be true not only as to the nutrient itself but [also as to] the
    product as a whole."            Id. at 655.        Greenberg rejected that
    argument based on the plain text of the FDCA.             A structure/function
    claim,    it    said,      "addresses    only    the   general   role    of   an
    - 15 -
    ingredient/nutrient on the human body," not "the product's health
    impact on the general population."                   Id. at 655–56.          Thus, the
    manufacturer need only have substantiation that its claim about
    "the ingredient's function on the human body" is truthful and not
    misleading.       Id. at 656.
    We     agree     with     Greenberg      that   the      plain    text     of
    § 343(r)(6)(B) requires a manufacturer to have substantiation that
    a nutrient's claimed effect on the human body's structure or
    function is truthful and not misleading, not that the product has
    the     claimed        effect.       Section     343(r)(6)(B)        requires        "the
    manufacturer of the dietary supplement [to] ha[ve] substantiation
    that such statement" -- i.e., the statement that describes the
    nutrient's effect on the human body's structure or function -- "is
    truthful    and        not   misleading."            Nowhere   in     the    text      of
    § 343(r)(6)(B) is the manufacturer required to show that taking
    the   dietary     supplement        affects    the    structure     or   function      as
    claimed.        See United States ex rel. Heineman-Guta v. Guidant
    Corp., 
    718 F.3d 28
    , 35 (1st Cir. 2013) ("We will not ordinarily
    read requirements into a statute that 'do not appear on its face.'"
    (quoting Dean v. United States, 
    556 U.S. 568
    , 572 (2009))).
    Had Congress wanted to add an efficacy requirement to
    § 343(r)(6)(B), it could have.                Products that are regulated as
    drugs    have     an    efficacy    requirement.         The   FDA    will    deny    an
    application to sell a new drug if, among other things, "there is
    - 16 -
    a lack of substantial evidence that the drug will have the effect
    it purports or is represented to have under the conditions of use
    prescribed, recommended, or suggested."               
    21 U.S.C. § 355
    (d); see
    also   Mut.    Pharm.   Co.    v.   Bartlett,   
    570 U.S. 472
    ,   476   (2013)
    (describing the new-drug application and approval process).                  And
    there is a reason why structure/function claims may not purport to
    treat disease and why a product bearing such claims must expressly
    repudiate any intention of treating disease:             A dietary supplement
    that makes a disease claim is regulated as a drug and must meet
    the    efficacy    requirement      discussed    above.        See   
    21 C.F.R. § 101.93
    (f); § 355(d).         So Congress knows how to add an efficacy
    requirement when it wants to and intentionally excluded one from
    structure/function claims.           See Guidant Corp., 
    718 F.3d at 35
    ("[W]hen Congress includes language in one section of a statute
    but omits it in another, 'it is generally presumed that Congress
    acts intentionally and purposely in the disparate inclusion or
    exclusion.'" (quoting Keene Corp. v. United States, 
    508 U.S. 200
    ,
    208 (1993))).
    There is more.    Congress found in the DSHEA that "safety
    problems with [dietary] supplements are relatively rare" and that
    "legislative action that protects the right of access of consumers
    to safe dietary supplements is necessary in order to promote
    wellness."      § 2(14), (15)(A), 108 Stat. at 4326.            It enacted the
    DSHEA to "ensur[e] that the Federal Government erects no barriers
    - 17 -
    that impede the ability of consumers to improve their nutrition
    through the free choice of safe dietary supplements" and "to
    clarify that dietary supplements are not drugs . . . [and] should
    not be regulated as drugs."        S. Rep. No. 103-410 (1994), 
    1994 WL 562259
    ,     at   *2.    Needless   to   say,   Congress    intended   dietary
    supplements to escape the regulatory gauntlet that drugs must go
    through.9
    The plaintiffs have a back-up argument.          Putting aside
    § 343(r)(6)(B)'s text, they contend that we must defer to the FDA's
    guidance     about     substantiation,    which,    they    say,   "requires
    substantiation of actual efficacy of the supplement."              It is true
    that the FDA's guidance opines that manufacturers should have
    evidence that their dietary supplements affect the human body's
    structure or function as claimed and under the conditions of use
    recommended on the products' labels.               Guidance for Industry,
    supra, Part II.B–D.        But the guidance calls itself a nonbinding
    9 Our conclusion is bolstered by several law review articles
    that the district court cited.    See Ferrari v. Vitamin Shoppe,
    Inc., No. 17-10475-GAO, 
    2022 WL 974048
    , at *3 (D. Mass. Mar. 31,
    2022). The DSHEA appears to be the result of intense lobbying by
    dietary supplement manufacturers and consumers in response to
    proposals to heavily regulate dietary supplements. See Lars Noah
    & Barbara A. Noah, A Drug by Any Other Name . . . ?: Paradoxes in
    Dietary Supplement Risk Regulation, 
    17 Stan. L. & Pol'y Rev. 165
    ,
    166 (2006); Peter J. Cohen, Science, Politics, and the Regulation
    of Dietary Supplements: It's Time to Repeal DSHEA, 
    31 Am. J.L. & Med. 175
    , 179–180 (2005); Stephen H. McNamara, Dietary Supplements
    of Botanicals and Other Substances: A New Era of Regulation, 
    50 Food & Drug L.J. 341
    , 341 (1995).
    - 18 -
    recommendation         "unless     specific        regulatory     or      statutory
    requirements are cited."           
    Id.
     Part I.A.; see also Greenberg, 985
    F.3d at 656 n.3 (stating that this guidance is "not on-point and
    in any event [is] not binding").               And we see no statutory or
    regulatory      authority        backing     its     opinion      that,     for     a
    structure/function claim to be substantiated within the meaning of
    § 343(r)(6)(B),        the   manufacturer     must   have   evidence      that    the
    nutrient plays the physiological role claimed under the conditions
    of use recommended on the label.            Assuming (without deciding) that
    the guidance is the type of agency interpretation warranting
    Chevron deference, see Doe v. Leavitt, 
    552 F.3d 75
    , 79–80 (1st
    Cir.   2009),    our    analysis    above    about    why   the   plain    text   of
    § 343(r)(6)(B)         only      requires      substantiation          that       the
    structure/function claim is truthful and not misleading dooms the
    plaintiffs' Chevron argument.          See Saysana v. Gillen, 
    590 F.3d 7
    ,
    16 (1st Cir. 2009) ("We have concluded that the text of the statute
    is clear.     Consequently, . . . there is nothing for the agency to
    interpret -- no gap for it to fill -- and there is no justification
    for resorting to agency interpretation to address an ambiguity.").
    We turn now to whether Vitamin Shoppe has substantiation
    that   its      structure/function         claims    are    truthful      and     not
    misleading.       Recall that substantiation requires competent and
    reliable scientific evidence.           The plaintiffs claim that Vitamin
    Shoppe put forward evidence only about how naturally occurring
    - 19 -
    glutamine –- not supplemental glutamine -- affects the human body's
    structure or function.   But the record tells a different story.
    Vitamin Shoppe's expert, Dr. Hoffman, presented a myriad of studies
    showing that glutamine supplementation supports immune health and
    muscle growth and recovery; is involved in regulating protein
    synthesis; has anti-catabolic effects, which help preserve muscle;
    and may help replenish glutamine stores after intense exercise.
    The plaintiffs' expert, Dr. Candow, attacked these studies on
    several grounds, including that they used higher doses of glutamine
    than Vitamin Shoppe's labels recommend, involved different forms
    of   administration   (e.g.,     intravenous),   incorporated     other
    additives, used animal subjects, and used disease-state human
    subjects.   In crafting his report, Dr. Candow evaluated Vitamin
    Shoppe's structure/function claims with respect to healthy humans
    at the doses recommended on the labels.    And after evaluating each
    claim   through   this   lens,     he   concluded   that   glutamine
    supplementation at the doses recommended is useless.            He did,
    however, agree that glutamine supplementation at some dose and for
    some people affects the human body's structure or function as
    Vitamin Shoppe's labels claim.    Because the plaintiffs assert that
    he was talking about naturally occurring glutamine when he said
    that, we will address each claim to show that there is no genuine
    dispute between the experts that supplemental glutamine plays the
    physiological role that Vitamin Shoppe's labels claim.
    - 20 -
    We start with the claim that glutamine supplementation
    supports muscle growth and recovery and immune health.       The
    following exchanges took place at Dr. Candow's deposition:
    Q. Now, going to the glutamine statement which
    says, "Glutamine helps support muscle growth
    and recovery as well as immune health."
    A. Okay.
    Q. Is it your opinion that this statement is
    false?
    A. Yes.    Specifically to the dose that is
    recommended.
    . . . .
    [Q.] At what dosage does glutamine help
    support immune health?
    A. I believe in all the articles the minimum
    dose was 10 grams a day.
    . . . .
    Q. Has glutamine supplementation been shown to
    decrease the incidence of infections?
    A. I believe so. I believe so, yes.
    Q. Has glutamine been shown to improve the
    response of cells in the immune system?
    A. Yes.
    . . . .
    Q. And do you disagree that glutamine
    supplementation can cause an increase in
    recovery?
    A. It can only at a specific dosage.
    Q. But in general, glutamine supplementation
    can increase recovery in the body?
    A. Again, at a specific dosage. So 1 gram,
    no. 2 grams or the dosage here is a specific
    dosage.
    Q.    What   is    the    dosage   at    which
    glutamine . . . supports recovery?
    A. I believe the minimal amount was 6 grams.
    . . . .
    Q. Glutamine supplementation can increase
    muscle   protein   synthesis 10 and    prevent
    10 Dr. Candow states in his report, "Muscle growth reflects
    the net balance between muscle protein synthesis and protein
    breakdown . . . . Muscle growth may be the result of a decrease
    in protein breakdown, an increase in protein synthesis, or both."
    - 21 -
    metabolism in certain situations.                Correct?
    A. That's correct.
    Thus, Dr. Candow's dispute with this structure/function claim
    comes down to the dose recommended on the product.                      The same is
    true    for   the    other   claims.       As    for     the   claim    that   taking
    supplemental        glutamine    after   intense       exercise    is    thought   to
    replenish depleted glutamine stores, leading to enhanced recovery,
    Dr. Candow agreed that, as a general matter, intense exercise can
    deplete glutamine stores and that glutamine supplementation can
    help maintain these stores and enhance recovery.                   He also agreed
    that supplemental glutamine is involved in regulating protein
    synthesis.        And he agreed that supplemental glutamine, in some
    circumstances such as in disease-state humans,11 has anti-catabolic
    properties,       which   help   preserve       muscle    tissue   by    preventing
    protein breakdown.        Thus, there is no genuine dispute that Vitamin
    Shoppe      has   substantiation    that    its    claims      about    supplemental
    glutamine's physiological role are truthful.
    The plaintiffs have one more arrow in their quiver.
    They argue that Vitamin Shoppe's labels are nonetheless misleading
    By agreeing that glutamine supplementation increases muscle
    protein synthesis, he agreed that glutamine supplementation
    supports muscle growth.
    Dr. Candow explained that humans might need more glutamine
    11
    than we naturally produce during times of extreme physical stress,
    such as trauma, cancer, HIV/AIDS, surgery, burns, sepsis,
    radiation, chemotherapy, and intense exercise.
    - 22 -
    because they       fail to reveal material facts about taking the
    supplements as recommended (i.e., that taking the supplements as
    recommended    does    nothing).          Section   343    governs   when   food
    products,    including    dietary    supplements,     are    misbranded.      
    21 U.S.C. § 343
    .      Section    321(n)    provides   that    when   evaluating
    whether a product is misbranded because the labeling is misleading,
    we must consider, among other things:
    [T]he extent to which the labeling . . . fails
    to reveal facts material in . . . light of
    [the] representations [on the label] or
    material with respect to consequences which
    may result from the use of the [product] to
    which the labeling . . . relates under the
    conditions of use prescribed in the labeling
    . . . thereof or under such conditions of use
    as are customary or usual.
    
    Id.
     § 321(n); see also Kaufman, 
    836 F.3d at 95
     ("This statutory
    command that we consider the omission of material facts fits hand-
    in-glove with the mandate of section 343(r)(6)(B) that the seller's
    substantiation show that a [claim] is both 'truthful and not
    misleading.'" (quoting § 343(r)(6)(B))).              The question here is
    whether    omitting    the   fact   that     glutamine     supplementation    is
    useless at the doses prescribed on the labels renders Vitamin
    Shoppe's claims about glutamine's physiological role misleading.
    In Greenberg, the Ninth Circuit answered no.               It reasoned that if
    a true claim such as "vitamin C boosts immunity" is misleading
    because most people do not need nor benefit from taking vitamin C,
    then     "virtually    any      structure/function        claim   for   dietary
    - 23 -
    supplements would potentially be misleading to the great majority
    of people" because most people are not walking around with vitamin
    deficiencies.        Greenberg, 985 F.3d at 656.         Such an outcome, it
    said, would conflict with the FDCA's text and Congress's purpose
    in enacting a regulatory carve-out for structure/function claims.
    Id.    We agree.     Section 343(r)(6)(B) requires the manufacturer to
    have     substantiation      that     its     claim    about   a     nutrient's
    physiological role is not misleading.            That taking the product as
    directed does not reap the benefits the label attributes to the
    nutrient has nothing to do with whether the nutrient's claimed
    physiological role is misleading.             See id. ("[M]anufacturers may
    make structure/function claims about a nutrient's general role on
    the human body without disclosing whether the product will provide
    a health benefit to each consumer.").
    To be sure, a structure/function claim is misleading if
    it omits a nutrient's conflicting or harmful role in affecting the
    human body's structure or function.            See Kaufman, 
    836 F.3d at
    95–
    96 (failing to disclose the nutrient's harmful effect on the human
    body's      structure        or     function       plausibly       renders      a
    structure/function       claim      misleadingly      incomplete).      And     a
    structure/function claim is untruthful if the nutrient does not
    have the claimed effect.          See Kroessler v. CVS Health Corp., 
    977 F.3d 803
    ,    812    (9th   Cir.   2020)   (reversing     dismissal    of    the
    plaintiff's complaint on preemption grounds where the plaintiff
    - 24 -
    alleged that glucosamine does not have the claimed effect on the
    human body's structure or function).          But this is not such a case.
    Because the experts here agree that Vitamin Shoppe's claims about
    glutamine's    physiological   role     are   truthful    and   there   is   no
    contention that these claims are misleading as to that role,
    Vitamin Shoppe has complied with § 343(r)(6)(B).
    IV.
    The   statements    about    glutamine   on    Vitamin   Shoppe's
    labels   are   structure/function      claims   under    § 343(r)(6).        And
    Vitamin Shoppe has complied with the FDCA's requirements to make
    such claims.     The plaintiffs' state law claims attacking those
    statements are therefore expressly preempted by the FDCA.                    The
    district court's judgment is affirmed.
    - 25 -